518 completed, 139 terminated, 85 unknown, 71 active not recruiting. 560 Phase 2, 286 Phase 1, 134 Phase 3, 23 Phase 4, 16 Not applicable.
Follow Bortezomib: new trials by email Literature Review of Bortezomib trials Research Report on Bortezomib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple Myeloma Anitocabtagene autoleucel, Daratumumab, Bortezomib - Newly Diagnosed Multiple Myeloma | Phase 3 | Not yet recruiting | Kite, A Gilead Company | 600 | 2027-01-01 | 2026-10-21 |
| Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple Myeloma Daratumumab and Recombinant Human Hyaluronidase, Lenalidomide, Bortezomib - Multiple Myeloma (MM) | Phase 2 / Phase 3 | Not yet recruiting | Alliance for Clinical Trials in Oncology | 920 | 2026-12-23 | 2026-10-22 |
| Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma Etentamig, Isatuximab, Bortezomib + Lenalidomide + Dexamethasone - Myeloma Multiple, Myeloma | Phase 1 / Phase 2 | Not yet recruiting | Universitätsklinikum Hamburg-Eppendorf | 220 | 2026-12-01 | 2026-05-20 |
| Study to Evaluate Change in Disease Activity and Adverse Events of Subcutaneous Etentamig Compared With Daratumumab Plus Cyclophosphamide Plus Bortezomib Plus Dexamethasone (Dara-CyBorD) in Adults With Amyloid Light Chain (AL) Amyloidosis Etentamig, Daratumumab, Cyclophosphamide - Amyloid Light Chain (AL) Amyloidosis | Phase 3 | Not yet recruiting | AbbVie | 370 | 2026-11-29 | 2026-08-28 |
| A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment Belantamab mafodotin, Bortezomib, Dexamethasone - Multiple Myeloma | Phase 1 | Not yet recruiting | GlaxoSmithKline | 20 | 2026-10-23 | 2026-05-27 |
| CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia CM336, Isatuximab, Bortezomib - Plasma Cell Leukemia (PCL) | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 24 | 2026-09-15 | 2026-09-18 |
| A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned Ramantamig, Daratumumab, Lenalidomide - Multiple Myeloma | Phase 3 | Recruiting | Janssen Research & Development, LLC | 1000 | 2026-09-09 | 2026-10-06 |
| Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed Myeloma Isatuximab, Iberdomide, Bortezomib - Newly Diagnosed Multiple Myeloma | Phase 1 / Phase 2 | Not yet recruiting | Dana-Farber Cancer Institute | 88 | 2026-09-03 | 2026-09-03 |
| Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma Arm A: Belantamab Mafodotin, Arm B: Daratumumab Hyaluronidase, Bortezomib - Multiple Myeloma | Phase 3 | Recruiting | PrECOG, LLC. | 500 | 2026-09-01 | 2026-08-17 |
| D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM Isatuximab, Iberdomide, Bortezomib (B) - Multiple Myeloma | Phase 3 | Recruiting | Dana-Farber Cancer Institute | 720 | 2026-08-31 | 2026-10-09 |
| Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | Children's Oncology Group | 1708 | 2026-08-28 | 2026-07-30 |
| Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple Myeloma Belantamab mafodotin, Dexamethasone, Bortezomib - Multiple Myeloma | Phase 2 | Not yet recruiting | GlaxoSmithKline | 150 | 2026-08-03 | 2026-06-24 |
| ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma Elranatamab (PF-06863135), Daratumumab and Hyaluronidase-fihj, Lenalidomide - Multiple Myeloma, Newly Diagnosed Multiple Myeloma | Phase 2 | Not yet recruiting | Massachusetts General Hospital | 160 | 2026-08-01 | 2026-06-23 |
| Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype Dexamethasone, Bortezomib, LENALIDOMIDE - Multiple Myeloma, Triple Negative Breast Cancer | Phase 1 | Recruiting | Andrew Hantel, MD | 90 | 2026-07-30 | 2026-08-17 |
| Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia methotrexate, rituximab, bortezomib - Hypophosphatasia | Phase 4 | Withdrawn | Alexion Pharmaceuticals, Inc. | 2026-07-29 | 2025-12-18 | |
| Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation Daratumumab, Lenalidomide, Bortezomib - Newly Diagnosed Multiple Myeloma, Multiple Myeloma | Phase 2 | Withdrawn | UNC Lineberger Comprehensive Cancer Center | 2026-07-01 | 2026-06-09 | |
| Phase I-II PTCy, Bortezomib and Sitagliptin for Prevention of GvHD Following Allogeneic HSCT Post transplant cyclophosphamide, bortezomib and sitagliptin in 3+3 design to MTD - GVHD - Graft-Versus-Host Disease | Phase 1 / Phase 2 | Not yet recruiting | Northwell Health | 72 | 2026-07-01 | 2026-06-30 |
| GMMG-HD11/DSMM XXI/64007957MMY3010 Teclistamab, Daratumumab, Lenalidomide - Multiple Myeloma | Phase 3 | Not yet recruiting | University of Heidelberg Medical Center | 399 | 2026-06-30 | 2026-06-26 |
| Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT AZD0120, Daratumumab, Dexamethasone - Newly Diagnosed Multiple Myeloma | Phase 3 | Recruiting | AstraZeneca | 750 | 2026-06-26 | 2026-08-14 |
| A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis Belantamab mafodotin, Cyclophosphamide, Bortezomib - Amyloidosis | Phase 2 | Recruiting | GlaxoSmithKline | 60 | 2026-06-24 | 2026-07-17 |
Showing 20 of 938. Sign in to see all of them.
Multiple Myeloma (455) · Neoplasms, Plasma Cell (69) · Recurrence (67) · Lymphoma, Mantle-Cell (66) · Lymphoma (65) · Lymphoma, Non-Hodgkin (43) · Lymphoma, Follicular (42) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (41) · Leukemia, Myeloid, Acute (36) · Lymphoma, Large B-Cell, Diffuse (34) · Waldenstrom Macroglobulinemia (33) · Lymphoma, B-Cell, Marginal Zone (30) · Leukemia, Lymphocytic, Chronic, B-Cell (28) · Immunoglobulin Light-chain Amyloidosis (25) · Carcinoma, Non-Small-Cell Lung (24)
National Cancer Institute (NCI) (91) · Millennium Pharmaceuticals, Inc. (30) · M.D. Anderson Cancer Center (27) · Janssen Research & Development, LLC (25) · Dana-Farber Cancer Institute (23) · University of Arkansas (20) · PETHEMA Foundation (18) · Mayo Clinic (15) · Memorial Sloan Kettering Cancer Center (14) · GlaxoSmithKline (12) · Emory University (11) · Celgene (9) · Massachusetts General Hospital (9) · Peking Union Medical College Hospital (8) · SWOG Cancer Research Network (8)
United States (591) · Spain (94) · France (93) · Germany (88) · China (87) · Canada (75) · Italy (73) · United Kingdom (65) · Australia (58) · South Korea (56) · Greece (53) · Belgium (50) · Poland (45) · Czechia (44) · Netherlands (43)
Maurizio Zangari, MD (6) · Paul Richardson, MD (6) · E. Steve Woodle, MD (4) · Irene Ghobrial, MD (4) · James R. Berenson, MD (4)
PMID 33357481, PMID 22689675, PMID 38023148, PMID 40501401, PMID 22674807, PMID 23897961, PMID 25261096, PMID 29567784, PMID 21791470, PMID 23305732, PMID 23603914, PMID 25824111, PMID 26771810, PMID 28293022, PMID 28419486, PMID 30957229, PMID 31221778, PMID 31231828, PMID 31576173, PMID 34289038, PMID 35132679, PMID 35876974, PMID 35985959, PMID 36184192, PMID 36882409, PMID 37393120, PMID 37990162, PMID 38062124, PMID 38826786, PMID 39321347, PMID 39863139, PMID 40763276, PMID 41627370, PMID 41671463, PMID 42212672, PMID 15365071, PMID 15613697, PMID 16061869, PMID 16135465, PMID 16135477, PMID 16971665, PMID 16983508, PMID 17075122, PMID 17353550, PMID 17409985, PMID 17488673, PMID 17553208, PMID 17679727, PMID 18053191, PMID 18090584
2023 (19), 2005 (10), P30CA015083 (10), U10CA021115 (10), U10CA031946 (8), U10CA032102 (8), 2008 (7), 2009 (7), 2014 (5), 2016 (5), 2017 (5), 2018 (5), 2025 (5), N01CM62204 (5), U01CA076576 (5)